Corvus Pharmaceuticals, Inc. $69 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc.

Credit Suisse, Jefferies, Guggenheim Securities and Wedbush PacGrow acted as underwriters on the offering.

The common stock is listed on the Nasdaq Global Market under the symbol “CRVS.”

Corvus is a clinical-stage biopharmaceutical company focused on the development of novel immuno-oncology therapies. The company, led by Richard A Miller, Leiv Lea and Joseph J Buggy, is based in Burlingame (CA).

The Davis Polk corporate team included partner Bruce K. Dallas (Picture) and associates Emily Roberts and Ali DeGolia. The tax team included partner Rachel D. Kleinberg and associate M. Brett Cameron. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Associate Colleen Blanco provided 1940 Act advice.

Involved fees earner: Bruce Dallas – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Ali DeGolia – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Brett Cameron – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell; Colleen Blanco – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Credit Suisse; Jefferies; Wedbush PacGrow;


Author: Ambrogio Visconti